Bring the immune system one step Ahead of cancer

An allogeneic platform designed to generate First-In-Class Tumors antigen-focused immunotherapies.
Changing a paradigm in oncology

0% of patients currently undergoing
treatment for solid tumors will experience treatment failure.

Our mission at Brenus is to fight relapsing diseases in cold solid tumors, which is currently the biggest unmet need in oncology.

Cancer = A moving target

The efficacy of current approaches is compromised by no anticipating tumor plasticity and resistances mechanisms and must be combined to be efficient.

Our science
Brenus Pharma’s solution educates patients’ immune system to anticipate and avoid their cancer relapse
STC platform
Key milestones validated

Represent heterogeneity of the targeted indication

Strict and AI assisted selection of Specific allogeneic Tumor cell lines to be the most representative of the targeted indication.

Read more
Represent heterogeneity of the targeted indication

Selection criteria of starting material (Allogeneic tumor cell lines)

  • Representative oncogenic drivers (TP53,BRAF,KRAS,…)
  • Cold & hot tumor cell lines
  • Resistances capacities (metabolic ; chemical & physical)
Back to the page

Increase antigenicity

Our STC manufacturing overpasses current approaches by covering a broad & higher-quality range of tumor antigens.

Read more
Increase antigenicity

Brenus’ manufacturing process overpasses the lack of antigenicity & educates the immune system  with a broad & higher quality range of tumor antigens

More about STC Antigenicity Back to the page

Increase immunogenicity

Haptenization process is a proven immunogenic tagging** sustainably boosting antigen’s immune recognition. It’s safely ensure immune system activation.

Read more
Increase immunogenicity

Brenus’ manufacturing process overpasses the lack of immunogenicity & educates the immune system  with visible and multi-specific targets

More about Haptenization & STC immunogenicity Back to the page

Stay tuned

See why engaging with us will bring about a change of paradigm.

Team

With the support of

Our awards

  • MATWIN 2021 award
  • Finalist 2022
  • BIOLABS MASTERCLASS
    Boston 2022
  • 2022 PRIX GALIEN USA AWARD NOMINEE
    "Best startup in the Pharmaceutical or Biotech industry"
  • ENRICH IN USA 2022 award